NLS Pharmaceutics AG (NLSP) has experienced an increase of 2.32% in the aftermarket. However, the last trading session closed at $2.59 with an incline of 1.97%.
NLSP to participate in Benzinga Healthcare Small-Cap Conference
NLSP announced on 24th September 2021 that Alex Zwyer, the company’s Chief Executive Officer and Co-Founder, will take part in a live interview. Also, they will meet with investors at the Benzinga Healthcare Small-Cap Conference, which will be placed digitally on September 29-30, 2021.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Phase 2 Trial for Quilience in Narcolepsy
NLSP stated Phase 2 Trial for Quilience in Narcolepsy on 14th September 2021. Quiliencease, a once-daily medication for the treatment of excessive daytime sleepiness (EDS) and cataplexy, the main symptoms of narcolepsy, has begun its Phase 2 clinical study. Furthermore, the trial will include 60 individuals with Type 1 and Type 2 narcolepsy who will be given either a 3mg dosage of Quilience (mazindol ER) once a day for 28 days or a placebo. t, yhe trial’s primary objective is the increase in EDS, as evaluated by the Epworth Sleepiness Scale (ESS), and a crucial secondary aim is an improvement in the mean weekly number of cataplexy events in the expected subgroup of cataplexy patients.
Appointment of Eric Konofal, M.D., Ph.D. as Chief Scientific Officer
NLSP announced the appointment of Eric on 19th July 2021. Eric Konofal is now the Chief Scientific Officer. Dr. Konofal is a co-founder with more than 30 years of experience as a physician in the field of sleep disorders and other CNS diseases.
Dr. Konofal is an expert drug hunter and drug pipeline developer. He is a senior medical consultant at the Robert-Debre University of Paris’s Pediatric Sleep Disorders Center (APHP). Moreover, Dr. Konofal worked as a Principal Clinical Investigator at the Robert-Debre University of Paris’ Clinical Pharmacology and Pharmacogenetic Department. His studies have focused on the interactions between the brain and iron in patients with neurological sleep disorders (RLS, PLMS).
New Study Data Confirming Mazindol’s Unique Orexin Pathway Activation by NLSP
NLSP revealed fresh research findings that back up the mechanism of action for mazindol on 18th May 2021. A lack of orexin, a neuropeptide that controls the sleep-wake cycle, causes narcolepsy. The new findings support mazindol’s agonist action at the Orexin-2 receptor (OX2R). Knock Out mice were 70% less susceptible to mazindol than normal mice. Lastly, this indicated mazindol’s strong action as an OX2R agonist, according to the study.